Published in J Cancer on November 23, 2013
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer | NCT01060514
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer | NCT00871403
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature. J Cancer (2016) 0.93
Tyrosine Kinase Inhibitors for the Elderly. J Cancer (2016) 0.91
Second-line afatinib administration in an elderly patient with squamous cell carcinoma. Ther Clin Risk Manag (2017) 0.82
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis (2014) 0.81
Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System. J Cancer (2014) 0.80
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? J Cancer (2015) 0.78
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Devel Ther (2014) 0.77
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer (2015) 0.76
A multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience. J Cancer (2014) 0.76
Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics. Oncotarget (2016) 0.76
Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in Sweden. J Thorac Dis (2015) 0.75
Cancer: we should not forget the past. J Cancer (2015) 0.75
Enhancement of Intratumoral Chemotherapy with Cisplatin with or without Microwave Ablation and Lipiodol. Future Concept for Local Treatment in Lung Cancer. J Cancer (2015) 0.75
Afatinib in Non-Small Cell Lung Cancer. J Adv Pract Oncol (2015) 0.75
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer. Dis Markers (2015) 0.75
Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer. Cancer Med (2016) 0.75
Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer. Arch Cancer Res (2016) 0.75
MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1. Oncol Lett (2016) 0.75
Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity? Med Hypothesis Discov Innov Ophthalmol (2016) 0.75
Targeted Lung Cancer Treatments and Eye Metastasis. Med Hypothesis Discov Innov Ophthalmol (2017) 0.75
DDMC-p53 gene therapy with or without cisplatin and microwave ablation. Onco Targets Ther (2015) 0.75
Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget (2017) 0.75
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50. Respir Med Case Rep (2017) 0.75
Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old. J Cancer (2017) 0.75
Fluorofenidone Inhibits the Proliferation of Lung Adenocarcinoma Cells. J Cancer (2017) 0.75
"Liquid elbows" due to afatinib administration. Respir Med Case Rep (2017) 0.75
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series. Respir Med Case Rep (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Lung cancer. N Engl J Med (2008) 13.49
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Multidisciplinary management of lung cancer. N Engl J Med (2004) 7.13
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) 5.11
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol (2005) 5.10
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med (1990) 4.66
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res (2002) 4.16
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol (2012) 4.15
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol (2007) 3.70
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 3.65
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol (2009) 3.42
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol (2008) 3.27
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol (2012) 2.98
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol (2010) 2.90
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.80
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol (2008) 2.64
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2006) 2.60
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol (2012) 2.52
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat (1995) 2.39
Epidemiology of lung cancer: looking to the future. J Clin Oncol (2005) 2.33
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer (2009) 2.27
Physical activity and cancer prevention--data from epidemiologic studies. Med Sci Sports Exerc (2003) 2.25
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res (2007) 2.22
The IGF system and breast cancer. Endocr Relat Cancer (2001) 2.21
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol (2007) 2.16
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 1.97
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol (2008) 1.93
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol (2007) 1.90
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.88
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol (2008) 1.86
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol (2001) 1.85
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol (2006) 1.81
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol (2009) 1.79
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (2012) 1.76
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 1.75
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.74
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Retracted Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2010) 1.69
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer (2012) 1.67
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol (2012) 1.58
Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control (2005) 1.58
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 1.57
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol (2006) 1.56
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55
Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol (2011) 1.54
The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol (2012) 1.53
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol (2008) 1.53
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
National survey of drug-resistant tuberculosis in China. N Engl J Med (2012) 6.28
Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res (2004) 3.78
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet (2008) 3.62
Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun (2009) 3.49
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Prevalence of smoking in China in 2010. N Engl J Med (2011) 3.38
A longitudinal assessment of the impact of smoke-free worksite policies on tobacco use. Am J Public Health (2005) 3.05
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54
Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care (2009) 2.41
Access to low-taxed cigarettes deters smoking cessation attempts. Am J Public Health (2005) 2.33
Methods of the International Tobacco Control (ITC) China Survey. Tob Control (2009) 2.30
A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. Mol Cell (2008) 2.15
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Detecting protein-protein interactions by Far western blotting. Nat Protoc (2007) 2.01
Copper ion liquid-like thermoelectrics. Nat Mater (2012) 1.92
Tobacco-free electronic cigarettes and cigars deliver nicotine and generate concern. Tob Control (2007) 1.92
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care (2008) 1.84
RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.80
Strokes after cardiac surgery and relationship to carotid stenosis. Arch Neurol (2009) 1.79
Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol (2003) 1.72
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res (2010) 1.71
Removal of tracheobronchial foreign bodies in adults using a flexible bronchoscope: experience with 200 cases in China. Intern Med (2012) 1.71
G8: a novel domain associated with polycystic kidney disease and non-syndromic hearing loss. Bioinformatics (2006) 1.71
Review of recent advances in analytical techniques for the determination of neurotransmitters. Anal Chim Acta (2009) 1.68
Findings from 2010 Global Adult Tobacco Survey: implementation of MPOWER policy in China. Biomed Environ Sci (2010) 1.65
Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis (2006) 1.64
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int (2012) 1.63
Catamenial pneumothorax: a rare entity? Report of 5 cases and review of the literature. J Thorac Dis (2012) 1.63
Synthesis of CeO2 nanorods via ultrasonication assisted by polyethylene glycol. Inorg Chem (2007) 1.60
Out of Tibet: Pliocene woolly rhino suggests high-plateau origin of Ice Age megaherbivores. Science (2011) 1.58
Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res (2009) 1.56
Role of structurally and magnetically modified nanoclusters in colossal magnetoresistance. Proc Natl Acad Sci U S A (2011) 1.55
Signaling components of redox active endosomes: the redoxosomes. Antioxid Redox Signal (2009) 1.50
Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation before endobronchial lung volume reduction. J Appl Physiol (1985) (2008) 1.49
Extrapelvic endometriosis: a rare entity or an under diagnosed condition? Diagn Pathol (2013) 1.49
Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis (2013) 1.49
Gene-by-diet interactions influence calcium absorption and bone density in mice. J Bone Miner Res (2014) 1.46
Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet (2006) 1.43
Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res (2006) 1.43
Gender differences in efficacy of primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Chin Med J (Engl) (2008) 1.42
Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract (2010) 1.42
Role of HCN channels in neuronal hyperexcitability after subarachnoid hemorrhage in rats. J Neurosci (2012) 1.42
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics (2009) 1.41
Effects of a flutter mucus-clearance device on pulmonary function test results in healthy people 85 years and older in China. Respir Care (2010) 1.40
Population-based survey of secondhand smoke exposure in China. Biomed Environ Sci (2010) 1.40
Midterm changes in quality of life: a prospective evaluation after open pulmonary metastasectomy. Ann Thorac Surg (2013) 1.39
Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. Pain Res Manag (2015) 1.39
Dermabrasion with steel wool in the extensive partial burns during shock stage: a case report and review. Burns (2007) 1.39
Detection of human metabolites using multi-capillary columns coupled to ion mobility spectrometers. J Chromatogr A (2005) 1.39
Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem (2002) 1.38
Perceptions of tobacco health warnings in China compared with picture and text-only health warnings from other countries: an experimental study. Tob Control (2010) 1.37
Successful application of extracorporeal membrane oxygenation due to pulmonary hemorrhage secondary to granulomatosis with polyangiitis. Drug Des Devel Ther (2013) 1.37
Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey. PLoS One (2013) 1.37
Graphene and nanowire transistors for cellular interfaces and electrical recording. Nano Lett (2010) 1.36
High current superconductivity in FeSe0.5Te0.5-coated conductors at 30 tesla. Nat Commun (2013) 1.36
Automated segmentation of lungs with severe interstitial lung disease in CT. Med Phys (2009) 1.36
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer (2007) 1.34
Automated hepatic volumetry for living related liver transplantation at multisection CT. Radiology (2006) 1.32
Ultralight multiwalled carbon nanotube aerogel. ACS Nano (2010) 1.32
Investigation of psychophysical measure for evaluation of similar images for mammographic masses: preliminary results. Med Phys (2005) 1.32
Quantitative computerized analysis of diffuse lung disease in high-resolution computed tomography. Med Phys (2003) 1.32
Toward intrinsic graphene surfaces: a systematic study on thermal annealing and wet-chemical treatment of SiO2-supported graphene devices. Nano Lett (2011) 1.28
Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. J Biol Chem (2011) 1.26
Complete genome sequence of Mycoplasma hyorhinis strain HUB-1. J Bacteriol (2010) 1.26
The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med (2006) 1.25
Computerized scheme for determination of the likelihood measure of malignancy for pulmonary nodules on low-dose CT images. Med Phys (2003) 1.25
Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res (2005) 1.24
A proteome reference map and proteomic analysis of Bifidobacterium longum NCC2705. Mol Cell Proteomics (2006) 1.22
Serum lipids and lipoproteins in Chinese men and women. Circulation (2012) 1.21
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer (2009) 1.21
Evidence for a superoxide permeability pathway in endosomal membranes. Mol Cell Biol (2008) 1.21
The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a cluster randomized trial. J Am Coll Cardiol (2012) 1.20
Lung Cancer Screening Using Low Dose CT Scanning in Germany. Dtsch Arztebl Int (2015) 1.19
Difficult airway and difficult intubation in postintubation tracheal stenosis: a case report and literature review. Ther Clin Risk Manag (2012) 1.18
Automated computerized scheme for distinction between benign and malignant solitary pulmonary nodules on chest images. Med Phys (2002) 1.18
Validity and reproducibility of a semi-quantitative food frequency questionnaire for use among pregnant women in rural China. Asia Pac J Clin Nutr (2008) 1.18
Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine (2012) 1.18
Cigarettes sold in China: design, emissions and metals. Tob Control (2010) 1.18
Dysfunctional connectivity patterns in chronic heroin users: an fMRI study. Neurosci Lett (2009) 1.16
A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. BMC Gastroenterol (2010) 1.16
Removal of glomus tumor in the lower tracheal segment with a flexible bronchoscope: report of two cases. Intern Med (2010) 1.16
Short sleep duration in prevalent and persistent psychological distress in young adults: the DRIVE study. Sleep (2010) 1.16
Radiologists' performance for differentiating benign from malignant lung nodules on high-resolution CT using computer-estimated likelihood of malignancy. AJR Am J Roentgenol (2004) 1.15
Application of flexible bronchoscopy in inhalation lung injury. Diagn Pathol (2013) 1.15